Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Odevo in connection with the acquisition of OBOS’ 40% minority stake in SBC and OBOS subsequent investment in Odevo
Mandate

Vinge advises Odevo in connection with the acquisition of OBOS’ 40% minority stake in SBC and OBOS subsequent investment in Odevo

April 13, 2022 M&A

Vinge advises Odevo in connection with the acquisition of OBOS minority stake of approx. 40 percent in SBC Intressenter HoldCo AB ("SBC") and OBOS’ subsequent investment in Odevo.

OBOS has been a minority investor in SBC since 2019. Through the divestment of its shares in SBC to Odevo, SBC becomes wholly owned by Odevo. Odevo was launched in February and is a new international player that challenges the traditional industry for property and housing management. The foundation for the group was created in 2019 through the formation of Nabo and the acquisition of SBC, and since then the group has grown into a leading international player. The companies within Odevo offer services to residents and property owners supported by Odevo’s own developed platform. The Odevo Group consists of a total of approximately 1,300 employees and has a turnover of just over SEK 1.5 billion.

Vinge’s team consisted of among others Jonas Bergstöm, Joacim Rydergård and Clara Sohlberg.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025